Aktis Oncology Funding & Investors
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.
aktisoncology.comTotal Amount Raised: $156,000,000
Aktis Oncology Funding Rounds
Series A
$84,000,000
Series A Investors
EcoR1 CapitalVida VenturesMRL Ventures FundMPM CapitalArrowMark PartnersNS InvestmentBristol-Myers SquibbCowenNovartisMirae Asset Venture InvestmentPappas CapitalOctagon Capital AdvisorsMerckTCG CrossoverSeries A
$72,000,000
Series A Investors
NovartisEcoR1 CapitalVida VenturesOctagon Capital AdvisorsMPM CapitalBristol-Myers SquibbTCG Crossover
Funding info provided by Diffbot.